Roth Capital initiated coverage of Healwell AI (HWAIF) with a Buy rating and C$2.50 price target The firm views Healwell as a “clinically validated” artificial intelligence vendor with scale and distribution. Following acquisitions and divestitures, the company is EBITDA positive and seeing synergies from deploying its Darwen AI technology, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HWAIF:
- HEALWELL AI Strengthens Board with Ian Kidson Appointment
- HEALWELL AI: Strong Financial Performance and Strategic Transformation Drive Buy Rating
- HEALWELL’s Earnings Call: Strong Growth Amid Challenges
- Healwell AI price target lowered to C$2.25 from C$2.75 at Alliance Global
- HEALWELL AI Reports Record Q3 Revenue and Strategic Growth